Related Experiment Video
Updated: Aug 8, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever
Guzide Aksu1, Can Ozturk, Kaan Kavakli
1Division of Immunology, Department of Pediatrics, Ege University Medical School, 35100, Bornova-Izmir, Turkey. guzide.aksu@ege.edu.tr
Clinical Rheumatology
|May 25, 2006
Summary
Familial Mediterranean fever (FMF) patients in remission show a hypercoagulable state, indicated by altered coagulation tests. This suggests subclinical inflammation may impact blood clotting, warranting further investigation in FMF management.
Area of Science:
- Rheumatology
- Hematology
- Internal Medicine
Background:
- Familial Mediterranean fever (FMF) is associated with chronic inflammation.
- Natural anticoagulant pathways are crucial for regulating inflammatory responses.
- Subclinical inflammation in FMF may affect the balance between clotting and anticoagulation.
Purpose of the Study:
- To investigate the anticoagulant-procoagulant status in FMF patients experiencing clinical remission.
- To determine if subclinical inflammation in FMF patients leads to a hypercoagulable state.
Main Methods:
- Twenty-seven attack-free FMF patients on colchicine treatment and 26 healthy controls were analyzed.
- Coagulation parameters including prothrombin time (PT), thrombin time (TT), protein C activity, and human prothrombin fragment F 1 + 2 levels were measured.
- Exclusion criteria included amyloidosis, autoimmunity, liver/renal disease, vasculitis, and thrombosis risk factors.
Main Results:
- While acute phase reactants were comparable to controls, PT, TT, protein C activity, and F 1 + 2 levels differed significantly.
- Shortened PT and TT, decreased protein C activity, and increased F 1 + 2 levels indicated a hypercoagulable state.
- Anti-streptolysin titers were significantly different compared to the control group.
Conclusions:
- FMF patients in remission exhibit a hypercoagulable state, likely due to persistent subclinical inflammation.
- Abnormal coagulation tests may help identify future complications related to inflammation in FMF.
- Larger studies are needed to confirm these findings and their clinical implications.
Related Concept Videos
01:06Coagulation
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...